Inhibikase Therapeutics (IKT) 10-Q 12 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	IKT
Entity Registrant Name	INHIBIKASE THERAPEUTICS, INC.
Entity Central Index Key	0001750149
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		25,227,051
Entity File Number	001-39676
Entity Current Reporting Status	Yes
Entity Tax Identification Number	26-3407249
Entity Address, Address Line One	3350 Riverwood Parkway SE
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	678
Local Phone Number	392-3419
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 32,212,276	$ 40,750,133
Accounts receivable	6,552	110,141
Prepaid research and development	919,053	107,000
Prepaid expenses and other current assets	811,482	1,502,725
Total current assets	33,949,363	42,469,999
Equipment and improvements	43,089
Total assets	33,992,452	42,469,999
Current liabilities:
Accounts payable	860,444	1,089,778
Accrued expenses and other current liabilities	3,629,861	2,715,761
Notes payable	0	248,911
Total liabilities	4,490,305	4,054,450
Commitments and contingencies (see Note 12)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2022, and December 31, 2021
Common stock, $0.001 par value; 100,000,000 shares authorized; 25,227,051 and 25,155,198 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively.	25,227	25,155
Additional paid-in capital	68,575,147	68,208,081
Accumulated deficit	(39,098,227)	(29,817,687)
Total	29,502,147	38,415,549
Total liabilities and stockholders' equity	$ 33,992,452	$ 42,469,999

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	25,227,051	25,155,198
Common stock, shares outstanding	25,227,051	25,155,198

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue	$ 6,552	$ 1,363,037	$ 52,583	$ 2,770,202
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:GrantMember	us-gaap:GrantMember	us-gaap:GrantMember	us-gaap:GrantMember
Costs and expenses:
Research and development	$ 2,982,183	$ 2,382,433	$ 5,999,174	$ 4,814,293
Selling, general and administrative	1,664,308	1,608,972	3,333,944	3,209,548
Total costs and expenses	4,646,491	3,991,405	9,333,118	8,023,841
Loss from operations	(4,639,939)	(2,628,368)	(9,280,535)	(5,253,639)
Interest expense		(7,811)	(5)	(19,608)
Net loss	$ (4,639,939)	$ (2,636,179)	$ (9,280,540)	$ (5,273,247)
Net loss per share - basic	$ (0.18)	$ (0.22)	$ (0.37)	$ (0.47)
Net loss per share - diluted	$ (0.18)	$ (0.22)	$ (0.37)	$ (0.47)
Weighted average number of common share basic	25,227,051	12,241,935	25,216,312	11,153,986
Weighted Average Number of Shares Outstanding, Diluted	25,227,051	12,241,935	25,216,312	11,153,986

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity - USD ($)	Total	June 2021 Offering	Common Stock	Common Stock June 2021 Offering	Additional Paid-In Capital	Additional Paid-In Capital June 2021 Offering	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ 9,784,356		$ 10,051		$ 24,805,929		$ (15,031,624)
Beginning balance, Shares at Dec. 31, 2020			10,050,849
Stock-based compensation expense	591,124				591,124
Warrant expense	237,768				237,768
Issuance of common stock	60,391		$ 9		60,382
Issuance of common stock, Shares			9,000
Net loss	(2,637,068)						(2,637,068)
Ending balance at Mar. 31, 2021	8,036,571		$ 10,060		25,695,203		(17,668,692)
Ending balance, Shares at Mar. 31, 2021			10,059,849
Beginning balance at Dec. 31, 2020	9,784,356		$ 10,051		24,805,929		(15,031,624)
Beginning balance, Shares at Dec. 31, 2020			10,050,849
Warrant expense	477,183
Net loss	(5,273,247)
Ending balance at Jun. 30, 2021	47,054,352		$ 25,134		67,334,089		(20,304,871)
Ending balance, Shares at Jun. 30, 2021			25,133,345
Beginning balance at Mar. 31, 2021	8,036,571		$ 10,060		25,695,203		(17,668,692)
Beginning balance, Shares at Mar. 31, 2021			10,059,849
Stock-based compensation expense	322,483				322,483
Warrant expense	239,415				239,415
Issuance of common stock		$ 41,135,357		$ 15,000		$ 41,120,357
Issuance of common stock, Shares				15,000,000
Issuance of common stock, stock options exercised	(43,295)		$ 74		(43,369)
Issuance of common stock, stock options exercised, Shares			73,496
Net loss	(2,636,179)						(2,636,179)
Ending balance at Jun. 30, 2021	47,054,352		$ 25,134		67,334,089		(20,304,871)
Ending balance, Shares at Jun. 30, 2021			25,133,345
Beginning balance at Dec. 31, 2021	$ 38,415,549		$ 25,155		68,208,081		(29,817,687)
Beginning balance, Shares at Dec. 31, 2021	25,155,198		25,155,198
Stock-based compensation expense	$ 123,229				123,229
Issuance of common stock	67,000		$ 50		66,950
Issuance of common stock, Shares			50,000
Issuance of common stock, stock options exercised	44,142		$ 22		44,120
Issuance of common stock, stock options exercised, Shares			21,853
Net loss	(4,640,601)						(4,640,601)
Ending balance at Mar. 31, 2022	34,009,319		$ 25,227		68,442,380		(34,458,288)
Ending balance, Shares at Mar. 31, 2022			25,227,051
Beginning balance at Dec. 31, 2021	$ 38,415,549		$ 25,155		68,208,081		(29,817,687)
Beginning balance, Shares at Dec. 31, 2021	25,155,198		25,155,198
Warrant expense	$ 0
Net loss	(9,280,540)
Ending balance at Jun. 30, 2022	$ 29,502,147		$ 25,227		68,575,147		(39,098,227)
Ending balance, Shares at Jun. 30, 2022	25,227,051		25,227,051
Beginning balance at Mar. 31, 2022	$ 34,009,319		$ 25,227		68,442,380		(34,458,288)
Beginning balance, Shares at Mar. 31, 2022			25,227,051
Stock-based compensation expense	132,767				132,767
Net loss	(4,639,939)						(4,639,939)
Ending balance at Jun. 30, 2022	$ 29,502,147		$ 25,227		$ 68,575,147		$ (39,098,227)
Ending balance, Shares at Jun. 30, 2022	25,227,051		25,227,051

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net loss	$ (9,280,540)	$ (5,273,247)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	255,996	913,607
Non-cash consulting fees	67,000	60,391
Non-cash PPP loan forgiveness	0	(27,550)
Warrant expense	0	477,183
Changes in operating assets and liabilities:
Grants receivable	103,589	(586,581)
Prepaid expenses and other assets	691,243	(779,126)
Prepaid research and development	(812,053)	(184,423)
Accounts payable	(229,334)	(837,705)
Accrued expenses and other current liabilities	890,416	239,837
Deferred revenue	23,684	(2,183,122)
Net cash used in operating activities	(8,289,999)	(8,180,736)
Investing activities
Purchases of equipment and improvements	43,089	0
Net cash used in investing activities	(43,089)	0
Financing activities
Proceeds from issuance of common stock	0	41,149,608
Issuance of common stock from exercise of stock options	44,142	34,357
Payment of employee taxes in connection with stock option exercise	0	(77,652)
Repayments of note payable	(248,911)	(42,534)
Net cash (used in) provided by financing activities	(204,769)	41,063,779
Net (decrease) increase in cash	(8,537,857)	32,883,043
Cash and cash equivalents at beginning of period	40,750,133	13,953,513
Cash and cash equivalents at end of period	32,212,276	46,836,556
Supplemental disclosures of cash flow information
Cash paid for interest	973	19,608
Non-cash financing activities
PPP loan forgiveness	$ 0	$ 27,550

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business Inhibikase Therapeutics, Inc. (the “Company,” “we” or “our”) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain. In 2021, we commenced clinical development of IkT-148009, a small molecule Abelson Tyrosine Kinase inhibitor we believe can modify the course of Parkinson’s disease including its manifestation in the gastrointestinal tract, or GI. Results to date of our completed Phase 1 Single and Multiple Ascending Dose escalation study (SAD and MAD, respectively) in older and elderly healthy volunteers have revealed important insights into the safety, tolerability and pharmacokinetics of IkT-148009 in human subjects. Results from the 88 older and elderly healthy Phase 1 subjects have shown that IkT-148009 has a half-life of greater than 24 hours and just a 25 mg once-daily oral dose reached exposures that are consistent with the exposures to the drug that resulted in therapeutic efficacy in animal models of progressive Parkinson’s disease. In July 2021, the U.S. Food and Drug Administration ("FDA"), agreed with the Company’s plan to initiate its Phase 1b study in Parkinson’s patients which commenced dosing October 19, 2021 and was closed June 2022 after two dosing cohorts. FDA review of the Phase 1/1b data and the protocol for the follow-on Phase 2a three-month dosing study resulted in the FDA agreeing with the Company’s view that it was appropriate for the Phase 2a study to begin, prompting the Company to close the Phase 1b study after two dosing cohorts. The Phase 2a ‘201 study’ began May 23, 2022 with the opening of the first site; we have opened 11 of 40 planned sites as of August 12, 2022. 120 treatment naïve patients are planned to be enrolled in this study which will dose patients with one of three planned doses of IkT-148009 or placebo once daily for three months. In addition to primary endpoints of safety/tolerability/pharmacokinetics, a hierarchy of 15 secondary endpoints measuring drug impact on motor and non-motor features of Parkinson’s disease in the brain or GI tract will be evaluated with descriptive statistics. Patients meeting the enrollment criteria are presently being scheduled for screening visits across open sites, with clinical readouts expected sometime in the second half of 2023. Our efforts in Parkinson’s disease are being extended into other Parkinson’s related indications, such as the orphan disease Multiple Systems Atrophy ("MSA"). Consistent with our efforts in Parkinson’s disease, our clinical pursuit of MSA depends on the outcome of animal studies modeling human MSA. In November 2020, the Company, along with its collaborators at Arizona State University, published evidence that the post-mortem MSA patient brain displayed evidence that the c-Abl kinase may play an important role in MSA, a role that mirrors the role of c-Abl in Parkinson’s. This observation prompted the initiation of two animal model studies to explore the ability of IkT-148009 to therapeutically treat MSA in animals. These model studies are ongoing and will be used to "gate" entry into clinical trials both in the U.S. and in the EU27 countries. The Company continues to prepare regulatory filings in the US and EU27 to enable the planned Phase 2 MSA trial if IkT-148009 is validated to be active in MSA in model studies. Our advancement of the pre-clinical and clinical development program for MSA has been aided by a grant from the National Institute of Neurological Diseases and Stroke, or NINDS, an Institute of the National Institutes of Health, for $ 385,888 to fund animal model studies of IkT-148009 as a therapy for MSA. The Phase 2a study proposed in MSA is planned as a safety and tolerability study in up to 19 sites in the EU27, and up to six sites in the U.S. involving 60 patients. Primary endpoints in safety and tolerability with secondary and exploratory endpoints in MSA efficacy parameters will be measured and assessed with descriptive statistics following-six month daily dosing at one of two doses. Execution of this trial will require the Company to raise additional working capital. On June 29, 2022, Inhibikase filed its Investigational New Drug Application ("IND") with the FDA in preparation to initiate clinical development of IkT-001Pro, the Company's prodrug of imatinib mesylate to treat Stable-phase Chronic Myelogenous Leukemia (SP-CML). IkT-001Pro will be evaluated in a two-part dose finding/dose equivalence study in up to 62 healthy volunteers. The study is designed to evaluate the steady-state pharmacokinetics of IkT-001Pro and determine the dose of IkT-001Pro equivalent to 400 mg imatinib mesylate, the standard-of-care dose for SP-CML. Assuming FDA permits the IND to proceed, Inhibikase expects to initiate this two-part bioequivalence study in the third or fourth quarter of 2022. Following the study, Inhibikase will confer with the FDA to begin the New Drug Application ("NDA") process following the proposed approval path for IkT-001Pro und the 505(b)(2) statute. The Company will simultaneously pursue a superiority study comparing the selected does of IkT-001Pro to standard-of-care 400 mg imatinib mesylate in SP-CML patients using a novel two-period wait list crossover switching study. In the ensuing 12 months, the Company anticipates reporting the full outcomes of its completed Phase 1/1b study of IkT-148009 in older and elderly healthy subjects and in Parkinson’s patients at the Movement Disorder Society Congress in September, 2022 reporting the outcomes of the completed chronic toxicology studies in rats and monkeys for IkT-148009 to enable chronic drug administration in Parkinson’s patients in September 2022, the initiation of the effect of food on the pharmacology of IkT-148009 and the initiation of an open-label safety extension study of IkT-148009 that would be initiated in patients who completed three-month dosing in the ‘201 study’ and possibly the initiation of a Phase 2a trial in MSA. These additional clinical studies to support clinical development of IkT-148009 will require additional capital for their completion. Our programs utilize small molecule, oral protein kinase inhibitors to treat PD and its GI complications. We have shown in animal models of progressive PD that our lead clinical candidate, IkT-148009, is a brain penetrant Abelson tyrosine kinase, or c-Abl inhibitor, that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract in animal models of human disease. We have not yet observed reversal of functional loss in humans with IkT-148009. The ability to halt progression and restore function was shown in animal models of progressive disease that mimic the rate of disease progression and the extent of functional loss in the brain and/or the GI tract as found in patients with PD. We believe our therapeutic approach would be disease-modifying. Our understanding of how and why PD progresses has led us to believe that functional loss in Parkinson’s patients may be at least partially reversed although this has not been shown clinically. Based on the measurements in animal models, it is possible that patients treated with IkT-148009 may have their disease progression slowed or halted, we may see a progressive reduction in the need for symptomatic or supportive therapy and/or we may ultimately eliminate the need for symptomatic therapy. However, as of the date of this Quarterly Report on Form 10-Q ("Report"), it is unknown whether any of the outcomes seen in the animal models will occur in patients following treatment with IkT-148009.

Liquidity

Liquidity	6 Months Ended
	Jun. 30, 2022
Disclosure Of Liquidity And Going Concern [Abstract]
Liquidity	2. Liquidity The Company has recognized recurring losses. At June 30, 2022, the Company had working capital of $ 29,459,058 , an accumulated deficit of $ 39,098,227 , cash of $ 32,212,276 , and accounts payable and accrued expenses of $ 4,490,305 . The Company had active grants in the amount of $ 385,888 , of which $ 314,228 remained available in accounts held by the U.S. Treasury as of August 1, 2022. The future success of the Company is dependent on its ability to successfully obtain additional working capital, obtain regulatory approval for and successfully launch and commercialize its product candidates and to ultimately attain profitable operations. Prior to its initial public offering in December 2020 (the “IPO”), the Company had funded its operations primarily through cash received in connection with revenue from its various grant programs. In addition, in June 2021 and December 2020, the Company raised approximately $ 41.1 million and $ 14.6 million in working capital from its underwritten public offering (the “June 2021 Offering”) and its IPO, respectively. The Company is subject to a variety of risks similar to other early-stage life science companies including, but not limited to, the successful development, regulatory approval, and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional working capital. The Company has incurred significant research and development expenses and general and administrative expenses related to its product candidate programs. The Company anticipates costs and expenses to increase in the future as the Company continues to develop its product candidates. The Company may seek to fund its operations through additional public equity, private equity, or debt financings, as well as other sources. However, the Company may be unable to raise additional working capital, or if it is able to raise additional capital, it may be unable to do so on commercially favorable terms. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations and financial condition and the Company’s ability to continue to develop its product candidates. The Company estimates that its working capital at June 30, 2022 is sufficient to fund its normal operations through December 31, 2023. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	3. Basis of Presentation and Significant Accounting Policies Basis of Presentation of Interim Financial Statements The accompanying unaudited condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. The December 31, 2021 balance sheet was derived from December 31, 2021 audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2022. The condensed unaudited consolidated financial statements contained herein should be read in conjunction with the Company’s annual audited financial statements and notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report filed on SEC Form 10-K. The unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which prescribes elimination of all significant intercompany accounts and transactions in the accounts of the Company and its wholly-owned subsidiary, IKT Securities Corporation, Inc., which was incorporated in the Commonwealth of Massachusetts in December 2021. Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Concentrations of Credit Risk For the three months ended June 30, 2022 and 2021 , the Company derived more than 90 % of its total revenue from a single source, the United States Government, in the form of federal research grants. Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s unaudited condensed consolidated statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before the grants are received. Leases The Company accounts for its leases under the ASU 2021-09, ASU 2018-10, and ASC Topic 842, Leases (“ASC 842”). ASC 842 requires a lessee to record a right-of-use asset and a corresponding lease liability for most lease arrangements on the Company's balance sheet. Under the standard, disclosure of key information about leasing arrangements to assist users of the financial statements with assessing the amount, timing and uncertainty of cash flows arising from leases is required. Equipment and Improvements Equipment and improvements are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated usefulness from three to five years for network equipment, office equipment, and furniture classified as fixed assets.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Balance Sheet Information	4. Supplemental Balance Sheet Information Accrued expenses and other current liabilities consist of the following: June 30, December 31, Accrued consulting $ 241,236 $ 210,000 Accrued compensation 311,147 421,734 Deferred revenue 23,684 — Accrued research and development 3,043,164 2,077,932 Accrued interest — 968 Accrued other 10,630 5,127 Total accrued expenses and other current liabilities $ 3,629,861 $ 2,715,761

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable Notes payable outstanding were $ 0 and $ 248,911 at June 30, 2022 and December 31, 2021, respectively. Revolving Demand Promissory Note On January 1, 2020, the Company issued a note (the “2020 Note”) in the face amount of $ 103,586 bearing 5.25 % APR simple interest. The 2020 Note was scheduled to mature on January 1, 2021 . Upon occurrence of certain conditions including the sale of a division of the Company or upon the date on which the Company closes on certain financings, the due date for some or all of the unpaid principal and accrued and unpaid interest may be accelerated. The Company assessed the terms and features of the 2020 Note and determined that none of the terms and features represented embedded derivatives that require bifurcation. On June 30, 2020, the holder of the 2020 Note and the Company entered into an agreement to settle the 2020 Note early. As full consideration and settlement of the 2020 Note’s June 30, 2020 principal balance plus accrued and unpaid interest in the amount of $ 106,334 , the Company issued a new promissory note to the holder in the amount of $ 42,534 (the “Fifth Restated Note”) with substantially similar terms as the 2020 Note. In addition, the holder subscribed for the purchase of 11,594 unregistered shares of the Company’s common stock at a subscription price of $ 63,800 , or $ 5.50 per share. The issuance of shares under the subscription agreement and the issuance of the Fifth Restated Note satisfied the payoff of the 2020 Note without premium or discount. The Fifth Restated Note was scheduled to mature on the earlier of a significant transaction, including an initial public offering, sale of substantially all assets or change of control, or January 1, 2021. The Company consummated its IPO on December 28, 2020 and the principal balance of the Fifth Restated Note plus accrued and unpaid interest was settled in full in cash on January 1, 2021. Note Payable to CEO On February 5, 2020 (the “Issue Date”), the Company issued a note payable to its CEO (the “CEO Note”) in the face amount of $ 245,250 bearing 1.59 % APR simple interest in exchange for cash. The net proceeds of $ 245,250 were used as working capital by the Company. The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note. If an event of default occurred and continued, the Company agreed to issue a warrant to the holder with a strike price of $ 4.87 per share for a number of shares equal to 150 % of the value of the loan. The Company assessed the terms and features of the CEO Note and determined that none of the terms and features represented embedded derivatives that require bifurcation. On June 13, 2020, the holder of the CEO Note and the Company entered into a restated agreement (the “CEO Restated Note”). The CEO Restated Note in the amount of $ 248,911 extended the stated maturity date of the CEO Note from the earlier of the sixth month following the (original) Issue Date or the date the Company has sufficient funds to repay the note to the earlier of the 30th month following the (original) Issue Date or the date the Company has sufficient funds to repay the CEO Restated Note. The Issue Date, February 5, 2020 , is unchanged. In addition, the interest rate was reduced, effective as of the Issue Date, from 1.59 % APR to 0.25 %. The CEO Restated Note also changed the exercise price of the warrant from $ 4.87 to $ 4.81 per share in the case of any default. The other provisions of the CEO Restated Note remained the same, in all material respects, to the CEO Note. The Company and its CEO agreed that the CEO Restated Note would not be repaid for a minimum of 12 months following the closing of its initial public offering. The principal balance of the CEO note was $ 248,911 at December 31, 2021. The principal balance plus accrued and unpaid interest on the CEO Note were settled in full, without adjustment, in cash on January 3, 2022. The Paycheck Protection Program Loan (the “PPP Loan”) On May 4, 2020 the Company received $ 27,550 in loan proceeds as part of the Federal CARES Act Paycheck Protection Program (the “CARES Act” or “PPP”) with a 1 % annual interest rate. The loan carried certain provisions to provide that if the Company expended not less than 60 % of the loan proceeds on qualified payroll costs, the principal and accrued interest on the loan would be forgiven . The lender and the Small Business Administration determined that the Company met the contractual conditions for forgiveness of the entire PPP Loan plus accrued interest and it was forgiven in 2021.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	6. Stockholders’ Equity Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding. As of June 30, 2022, a total of 5,599,313 shares of common stock were reserved for issuance upon the exercise of outstanding stock options and warrants under the 2020 Equity Incentive Plan (the "2020 Plan") and the 2011 Equity Incentive Plan. Share Issuances In March 2021, an accredited investor subscribed for, and the Company issued, 9,000 shares of its stock in exchange for consulting services. The fair value of the stock was $ 60,391 based upon the closing price of the shares on the date of the transaction. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. The $ 60,391 fair value was a component of selling, general and administrative costs for the six months ended June 30, 2021. In connection with the June 2021 Offering, the Company issued and sold 15,000,000 fully paid non-assessable shares of its common stock at a public offering price of $ 3.00 per share. Proceeds from the June 2021 Offering were $ 41.1 million after deducting offering costs, underwriting discounts and commissions of approximately $ 3.9 million. In January 2022, the Company issued 21,853 shares of its common stock in connection with the exercise of non-qualified stock options with a strike price of $ 2.02 per share. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. This issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act as transactions by an issuer not involving any public offering. In February 2022, an accredited investor subscribed for, and the Company issued 50,000 shares of its stock in exchange for consulting services. The fair value of the stock was $ 67,000 based upon the closing price of the shares on the date of the transaction. Issuance costs were not material. No additional rights or options were granted to this accredited investor in connection with this issuance. This issuance is exempt from registration pursuant to Section 4(a)(2) of the Securities Act as transactions by an issuer not involving any public offering.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation 2020 Equity Incentive Plan The Company’s 2020 Plan was established for granting stock incentive awards to directors, officers, employees and consultants to the Company. Stock Options During the six months ended June 30, 2022 , the Company granted 160,000 options and 239,887 options to purchase its common stock to its directors and certain employees, respectively. The director option grants will cliff vest on the sooner to occur of one year from the grant date or the day prior to the 2023 annual meeting. The employee grants will vest annually in three equal parts over three years. The weighted average strike price and the aggregate grant date fair value of these options is $ 0.97 and $ 248,055 , respectively. During the six months ended June 30, 2021 , the Company granted 68,628 options to purchase common stock to its scientific advisory board members with a strike price of $ 6.82 per share, vesting immediately, with an aggregate grant date fair value of $ 259,674 . On June 25, 2021, the Company granted a total of 90,708 options to members of its board of directors with a strike price of $ 2.92 per share, vesting one year from the date of the grant, with an aggregate grant date fair value of $ 160,000 . Stock-Based Compensation Expense The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees: Six Months Ended June 30, 2022 2021 Research and development $ 192,991 $ 480,415 Selling, general and administrative 63,005 433,192 Total stock-based compensation expense $ 255,996 $ 913,607

Warrants

Warrants	6 Months Ended
	Jun. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	8. Warrants The Company recognized $ 237,768 and $ 477,183 in warrant expense for the three and six months ended June 30, 2021, respectively, included in selling, general and administration expense.

ATM program

ATM program	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
ATM program	9. ATM program On May 16, 2022, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Piper Sandler & Co. as sales agent (the “Agent”), pursuant to which the Company may, from time to time, issue and sell shares of its Common Stock, at an aggregate offering price of up to $ 9.8 million (the “Shares”) through the Agent. Under the terms of the Agreement, the Agent may sell the Shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act, as amended. Subject to the terms and conditions of the Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the Agreement or terminate the Agreement in accordance with its terms. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a fixed commission of 3.0 % of the aggregate gross proceeds from the Shares sold. The Agreement contains customary representations and warranties, and the Company is required to deliver customary closing documents and certificates in connection with sales of the Shares. As of June 30, 2022, no Shares have been sold under the Agreement.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: Six Months Ended June 30, 2022 2021 Numerator: Net loss $ ( 9,280,540 ) $ ( 5,273,247 ) Denominator: Weighted-average number of common shares 25,216,312 11,153,986 Net loss per share applicable to common $ ( 0.37 ) $ ( 0.47 ) T he following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: Six Months Ended June 30, 2022 2021 Options to purchase shares of stock 4,037,400 3,624,657 Warrants to purchase shares of stock 1,561,913 1,561,913 Total 5,599,313 5,186,570

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes During the six months ended June 30, 2022 and 2021 , there was no provision for income taxes as the Company incurred losses during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company recorded a full valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Impact of the COVID-19 Pandemic on Our Operations There continues to be widespread impact from the COVID-19 pandemic. Beginning in the first quarter of 2021, there has been a trend in many parts of the world of increasing availability and administration of vaccines against COVID-19, as well as an easing of restrictions on social, business, travel and government activities and functions. On the other hand, infection rates and regulations continue to fluctuate in various regions and there are ongoing global impacts resulting from the pandemic, including challenges and increases in costs for logistics and supply chains. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical and long-lasting and may vary from location to location. In addition, we have experienced and are experiencing varying levels of inflation resulting in part from various supply chain disruptions, increased shipping and transportation costs, increased raw material and labor costs and other disruptions caused by the COVID-19 pandemic and general global economic conditions. The COVID-19 pandemic has caused significant, industry-wide delays in clinical trials. There are multiple causes of these delays, including reluctance of patients to enroll or continue in trials for fear of exposure to COVID-19, local and regional shelter-in-place orders and regulations that discourage, hamper, or prohibit patient visits, healthcare providers and health systems shifting away from clinical trials toward the acute care of COVID-19 patients and the FDA and other regulators making product candidates for the treatment of COVID-19 a priority over product candidates unrelated to the pandemic. As a result of the COVID-19 pandemic, commencement of enrollment in our clinical trials may be delayed. In addition, after enrollment in these trials, if patients contract COVID-19 during participation in the Company’s trials or are subject to isolation or shelter-in-place restrictions, this may cause them to drop out of the Company’s trials, miss scheduled doses or follow-up visits or otherwise fail to follow trial protocols. If patients are unable to follow the trial protocols or if the Company’s trial results are otherwise affected by the consequences of the COVID-19 pandemic on patient participation or actions taken to mitigate COVID-19 spread, the integrity of data from the Company’s trials may be compromised or not accepted by the FDA or other regulatory authorities, which could impact or delay a clinical development program. The Company anticipates that the COVID-19 pandemic may also impact manufacturing and distribution of materials necessary for the conductance of its clinical trials. Although the Company did not experience a material impact on its operations during the six months ended June 30, 2022 and 2021, the Company notes the high level of difficulty in determining the future potential adverse financial impact and other effects of COVID-19 on the Company and its programs, given the rapid and dramatic evolution in the course and impact of the pandemic and the societal and governmental response to it. Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability would include probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. Lease On April 18, 2022, the Company entered into an operating lease agreement for its planned office space in Lexington, Massachusetts through July 31, 2025 (the "Office Lease"). As of June 30, 2022, the lessor was continuing to undertake extensive renovations of this space. During the period of renovation, the Company has no access to, control over or possession of the premises. The Company will account for the Office Lease under the provisions of ASU No. 2021-09, ASU 2018-10, and ASC 842. As of June 30, 2022, the accounting commencement date had not occurred. We expect to record a right-of-use asset and a corresponding lease liability on the Company's consolidated balance sheet in the period when the accounting commencement date occurs. It is anticipated that this will happen during the third quarter of 2022. The lease contains escalating payments during the lease period. Upon execution of this lease agreement, the Company prepaid one month of rent and a security deposit, one of which will be held in escrow and credited at the termination of the lease and the other of which will be applied to the first month’s rent. As of June 30, 2022 , a security deposit of approximately $ 25,000 was included in prepaid expenses and other current assets on the Company’s condensed consolidated balance sheet related to the Office Lease. Future minimum lease payments under these leases at June 30, 2022 are as follows: Year 2022 $ 60,322 2023 146,546 2024 150,804 2025 89,418 Total lease payment $ 447,090

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Minimum Bid Price of Common Stock: In order for our common stock to continue to be listed on Nasdaq, we must meet the current continued listing requirements, which provide, among other things, that a company may be delisted if the bid price of its stock drops below $ 1.00 for a period of 30 consecutive business days. As of July 22, 2022, the closing price of our common stock was $ 0.91 per share, and the minimum bid price fell below $ 1.00 for a period of thirty consecutive trading days. The Company has a compliance period of 180 days in which to regain compliance. The 180-day period expires on January 23, 2023. If at any time during this 180-day period the closing price of the Company's stock is at least $1.00 for a minimum of ten consecutive business days, the Company will regain compliance with the rule for minimum bid price. In the event the Company does not regain compliance, the Company may be eligible for additional time under certain Nasdaq rules.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation of Interim Financial Statements	Basis of Presentation of Interim Financial Statements The accompanying unaudited condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. The December 31, 2021 balance sheet was derived from December 31, 2021 audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2022. The condensed unaudited consolidated financial statements contained herein should be read in conjunction with the Company’s annual audited financial statements and notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report filed on SEC Form 10-K. The unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which prescribes elimination of all significant intercompany accounts and transactions in the accounts of the Company and its wholly-owned subsidiary, IKT Securities Corporation, Inc., which was incorporated in the Commonwealth of Massachusetts in December 2021. Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are generally adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. The JOBS Act permits an emerging growth company such as the Company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that it either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company utilizes certain estimates in the determination of the fair value of its stock options and warrants, deferred tax valuation allowances and revenue recognition, to record expenses relating to research and development contracts and accrued expenses. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk For the three months ended June 30, 2022 and 2021 , the Company derived more than 90 % of its total revenue from a single source, the United States Government, in the form of federal research grants.
Revenue Recognition	Revenue Recognition The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s unaudited condensed consolidated statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before the grants are received.
Leases	Leases The Company accounts for its leases under the ASU 2021-09, ASU 2018-10, and ASC Topic 842, Leases (“ASC 842”). ASC 842 requires a lessee to record a right-of-use asset and a corresponding lease liability for most lease arrangements on the Company's balance sheet. Under the standard, disclosure of key information about leasing arrangements to assist users of the financial statements with assessing the amount, timing and uncertainty of cash flows arising from leases is required.
Equipment and Improvements	Equipment and Improvements Equipment and improvements are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated usefulness from three to five years for network equipment, office equipment, and furniture classified as fixed assets.

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consist of the following: June 30, December 31, Accrued consulting $ 241,236 $ 210,000 Accrued compensation 311,147 421,734 Deferred revenue 23,684 — Accrued research and development 3,043,164 2,077,932 Accrued interest — 968 Accrued other 10,630 5,127 Total accrued expenses and other current liabilities $ 3,629,861 $ 2,715,761

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees	The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees: Six Months Ended June 30, 2022 2021 Research and development $ 192,991 $ 480,415 Selling, general and administrative 63,005 433,192 Total stock-based compensation expense $ 255,996 $ 913,607

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders	The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders: Six Months Ended June 30, 2022 2021 Numerator: Net loss $ ( 9,280,540 ) $ ( 5,273,247 ) Denominator: Weighted-average number of common shares 25,216,312 11,153,986 Net loss per share applicable to common $ ( 0.37 ) $ ( 0.47 )
Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders	he following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented: Six Months Ended June 30, 2022 2021 Options to purchase shares of stock 4,037,400 3,624,657 Warrants to purchase shares of stock 1,561,913 1,561,913 Total 5,599,313 5,186,570

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future minimum lease payments under these leases at June 30, 2022 are as follows: Year 2022 $ 60,322 2023 146,546 2024 150,804 2025 89,418 Total lease payment $ 447,090

Nature of Business (Additional

Nature of Business (Additional Information) (Details)	Jun. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Grant received to fund animal model studies	$ 385,888

Liquidity - Additional Informat

Liquidity - Additional Information (Details) - USD ($)		3 Months Ended
	Aug. 01, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital					$ 29,459,058
Accumulated deficit					(39,098,227)	$ (29,817,687)
Cash					32,212,276	$ 40,750,133
Accounts payable and accrued expenses					$ 4,490,305
Issuance of common stock	$ 385,888	$ 67,000		$ 60,391
Treasury share held	$ 314,228
June 2021 Offering
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital			$ 41,100,000
Issuance of common stock			$ 41,135,357
IPO
Disclosure Of Liquidity And Going Concern [Line Items]
Working capital							$ 14,600,000

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies - Additional Information (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2020
Summary Of Significant Accounting Policies [Line Items]
Common stock, par value	$ 0.001		$ 0.001	$ 0.001	$ 5.50
Minimum | Network Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P3Y
Minimum | Office Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P3Y
Minimum | Furniture
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P3Y
Maximum | Network Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P5Y
Maximum | Office Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P5Y
Maximum | Furniture
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives			P5Y
Customer Concentration Risk | Sales Revenue | Minimum
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	90%	90%

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued consulting	$ 241,236	$ 210,000
Accrued compensation	311,147	421,734
Deferred revenue	23,684	0
Accrued research and development	3,043,164	2,077,932
Accrued interest	0	968
Accrued other	10,630	5,127
Total accrued expenses and other current liabilities	$ 3,629,861	$ 2,715,761

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) - USD ($)				1 Months Ended	3 Months Ended	6 Months Ended
	May 04, 2020	Feb. 05, 2020	Jan. 01, 2020	Jun. 30, 2020	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Jun. 13, 2020
Debt Instrument [Line Items]
Annual interest rate		1.59%
Shares subscribed for purchase				11,594
Share subscription price				$ 63,800
Common stock, par value				$ 5.50		$ 0.001	$ 0.001
Notes payable outstanding balance						$ 0	$ 248,911
Strike price		$ 4.87
Issue date		Feb. 05, 2020
Principal Balance
Debt Instrument [Line Items]
Notes payable, net of current portion							$ 248,911
2020 Note
Debt Instrument [Line Items]
Annual interest rate			5.25%
Debt instrument face amount			$ 103,586
Maturity date			Jan. 01, 2021
Settlement of notes including principal balance plus accrued and unpaid interest				$ 106,334
Fifth Restated Note
Debt Instrument [Line Items]
Debt instrument face amount				$ 42,534
CEO Note
Debt Instrument [Line Items]
Annual interest rate		1.59%
Debt instrument face amount		$ 245,250
Net proceeds		$ 245,250
Maturity description						The note carried an original maturity of the earlier of the sixth month following the Issue Date or the date the Company has sufficient funds to repay the CEO Note.
Strike price		$ 4.87
Percentage of number of shares to value of loan		150%
On event of default					If an event of default occurred and continued, the Company agreed to issue a warrant to the holder with a strike price of $4.87 per share for a number of shares equal to 150% of the value of the loan.
C E O Restated Note
Debt Instrument [Line Items]
Annual interest rate								0.25%
Debt instrument face amount								$ 248,911
Strike price								$ 4.81
Paycheck Protection Program
Debt Instrument [Line Items]
Annual interest rate	1%
Net proceeds	$ 27,550
Percentage of loan proceeds expended on qualified payroll costs	60%
Loan forgiveness terms						if the Company expended not less than 60% of the loan proceeds on qualified payroll costs, the principal and accrued interest on the loan would be forgiven

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)	1 Months Ended			6 Months Ended
	Feb. 28, 2022 USD ($) shares	Jan. 31, 2022 $ / shares shares	Mar. 31, 2021 USD ($) shares	Jun. 30, 2022 USD ($) Vote $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2021 $ / shares	Jun. 30, 2020 $ / shares
Class Of Stock [Line Items]
Votes per each common stock share | Vote				1
Common stock shares reserved for issuance				5,599,313
Common stock, par value | $ / shares				$ 0.001		$ 0.001	$ 5.50
Proceeds from issuance of common stock | $				$ 0	$ 41,149,608
Additional rights or options granted		0
Common stock in connection with exercise of non-qualified stock options, Shares		21,853
Stock option strike price | $ / shares		$ 2.02
Consulting Services
Class Of Stock [Line Items]
Additional rights or options granted	0		0
Shares issued in exchange for consulting services	50,000		9,000
Fair value of stock issued in exchange for consulting services | $	$ 67,000		$ 60,391
Consulting Services | Selling, General and Administrative
Class Of Stock [Line Items]
Fair value of stock issued in exchange for consulting services | $			$ 60,391
June 2021 Offering
Class Of Stock [Line Items]
Shares issued price per share | $ / shares					$ 3
Proceeds from issuance of common stock | $					$ 41,100,000
Issued and sold fully paid non-assessable shares of common stock					15,000,000
Offering costs, underwriting discounts and commissions | $					$ 3,900,000

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)		6 Months Ended
	Jun. 25, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of stock options granted		160,000	68,628
Number of stock issued		239,887
Stock option, strike price		$ 0.97	$ 6.82
Stock option, aggregate grant date fair value		$ 248,055	$ 259,674
Board of Director Member
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of stock options granted	90,708
Stock option, strike price	$ 2.92
Stock option, aggregate grant date fair value	$ 160,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 255,996	$ 913,607
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	192,991	480,415
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 63,005	$ 433,192

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Feb. 05, 2020
Class Of Warrant Or Right [Line Items]
Strike price					$ 4.87
Warrant expense	$ 239,415	$ 237,768	$ 0	$ 477,183
Selling, General and Administrative
Class Of Warrant Or Right [Line Items]
Warrant expense	$ 237,768			$ 477,183

ATM program (Additional Informa

ATM program (Additional Information) (Details) - Equity Distribution Agreement - USD ($) $ in Millions	May 16, 2022	Jun. 30, 2022
Marketable Securities [Line Items]
Common stock Aggregate offering price	$ 9.8
Fixed commission percentage		3%

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net loss	$ (4,639,939)	$ (4,640,601)	$ (2,636,179)	$ (2,637,068)	$ (9,280,540)	$ (5,273,247)
Denominator:
Weighted average number of common share basic	25,227,051		12,241,935		25,216,312	11,153,986
Weighted average number of common share Diluted	25,227,051		12,241,935		25,216,312	11,153,986
Net loss per share applicable to common stockholders - basic	$ (0.18)		$ (0.22)		$ (0.37)	$ (0.47)
Net loss per share applicable to common stockholders - diluted	$ (0.18)		$ (0.22)		$ (0.37)	$ (0.47)

Net Loss Per Share - Summary _2

Net Loss Per Share - Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	5,599,313	5,186,570
Options to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	4,037,400	3,624,657
Warrants to Purchase Shares of Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted net loss per share	1,561,913	1,561,913

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0

Commitments and Contingencies_2

Commitments and Contingencies (Additional Information) (Details) - USD ($)	Apr. 18, 2022	Jun. 30, 2022
Prepaid Expenses and Other Current Assets [Member]
Lessor, Lease, Description [Line Items]
Security deposit		$ 25,000
Lexington
Lessor, Lease, Description [Line Items]
Lease Expiration Date	Jul. 31, 2025
Lessor, Operating Lease, Description	The lease contains escalating payments during the lease period. Upon execution of this lease agreement, the Company prepaid one month of rent and a security deposit, one of which will be held in escrow and credited at the termination of the lease and the other of which will be applied to the first month’s rent.

Commitments and Contingencies -

Commitments and Contingencies - Summary of Future minimum lease payments (Details)	Jun. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 60,322
2023	146,546
2024	150,804
2025	89,418
Total lease payment	$ 447,090

Subsequent Events - Additional

Subsequent Events - Additional Information (Details)	Jul. 22, 2022 USD ($) $ / shares	Jun. 30, 2022 USD ($)
Subsequent Event [Line Items]
Bid Price of Stock Drops		1
Subsequent Event [Member]
Subsequent Event [Line Items]
Bid Price of Stock Drops	1
Closing Price of Common Stock | $ / shares	$ 0.91
Subsequent Event, Description	As of July 22, 2022, the closing price of our common stock was $0.91 per share, and the minimum bid price fell below $1.00 for a period of thirty consecutive trading days.  The Company has a compliance period of 180 days in which to regain compliance. The 180-day period expires on January 23, 2023. If at any time during this 180-day period the closing price of the Company's stock is at least $1.00 for a minimum of ten consecutive business days, the Company will regain compliance with the rule for minimum bid price. In the event the Company does not regain compliance, the Company may be eligible for additional time under certain Nasdaq rules.